Swissmedic

Type: Organization

Name: Swissmedic

First reported 14 hours ago - Updated 7 hours ago - 2 reports

CORRECTED-Amag investigates anemia drug after report of death in Switzerland

1:24am BST(Corrects headline to "investigates." Amag did not say the drug caused the fatality.)May 21 (Reuters) - Amag Pharmaceuticals Inc said its marketing partner in Switzerland, Takeda Pharmaceutical Co Ltd, is recalling a batch of Amag's anemia drug, ... [Published Reuters UK - 11 hours ago]

Entities: anemia, Switzerland, Drugs, Takeda Pharmaceutical Co Ltd, Feraheme

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Geneva cancer specialist wins new US award

GENEVA, SWITZERLAND – Pierre-Yves Dietrich has been awarded the “First annual cancer researcher of the year award by the Gateway for Cancer Research Foundation in the US, with prize money of $30,000 and additional financing worth $500,000 for clinical ... [Published GenevaLunch - May 17 2013]

Entities: Geneva, Cancer, Brain Cancer, Swissmedic

First reported May 07 2013 - Updated May 07 2013 - 2 reports

Roche Holding AG

Roche's Kadcyla Breast Cancer Drug Approved For Swiss Use

Roche Holding AG (ROG.VX) Tuesday said the Swiss drug regulatory and supervisory authority (Swissmedic) has approved Kadcyla, Roche's new medicine for treating an aggressive form of breast cancer. ... [Published FOXBusiness.com - May 07 2013]

Entities: Kadcyla, Breast Cancer, Swissmedic, Roche Holding AG

First reported May 02 2013 - Updated May 03 2013 - 1 reports

Arena Pharmaceuticals Inc

Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results

/PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2013.Recent Developments:BELVIQ(® )(lorcaserin HCl)-- The American Association of Clinical ... [Published NewsBlaze - May 02 2013]

Entities: Arena Pharmaceuticals Inc, Eisai Inc., Body Mass Index

First reported May 03 2013 - Updated May 03 2013 - 2 reports

Arena pulls obesity drug Belviq application in EU

EMA asks for more dataEU regulators have signalled their reluctance to approve new drugs for obesity once again by asking for more data on Arena Pharmaceuticals' Belviq.Arena said the European Medicines Agency's (EMA) Committee for Medicinal Products ... [Published PMLive - May 03 2013]

Entities: Obesity, Drugs, Qsymia, European Medicines Agency, Jack Lief

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Foundation ups drugs checks

The fight against doping in sport goes on (Keystone)The Antidoping Switzerland foundation carried out a record number of screening tests in 2012 – a total of 3,140. It fulfilled all of the tasks assigned to it by Swiss Olympic and the government, according ... [Published Swiss Info - Apr 15 2013]

Entities: Doping, Switzerland, Anti-Doping, Drugs, London Olympics 2012

Quotes

"The batch was only distributed to and sold in Switzerland and the recall is limited to the specific batch and specifically Switzerland" Lexington, Massachusetts-based Amag said in a regulatory filing on Tuesday. (r.reuters.com/fek38t)

CORRECTED-Amag investigates anemia drug after report of death in Switzerland [Published Reuters UK - 11 hours ago]

...value of perampanel in the treatment of partial seizures," noted Professor Bernhard Steinhoff from the Epilepsiezentrum Kork, Kehl-Kork, Germany. $ "Up to 40% of patients with epilepsy are, or become, refractory to treatment, potentially resulting in impaired quality of life and an increased risk of injury or unexpected sudden death. There is a real need for effective new AEDs with novel modes of action that can be given with the most commonly prescribed AEDs. Perampanel is therefore a very welcome new adjunctive therapy."

First-in-class Fycompa® (perampanel) Pooled Pivotal Phase III Data Published in Epilepsia [Published Sys-Con Australia - May 13 2013]

"Die Ergebnisse dieser frühen Studien sind ein vielversprechendes Indiz für den klinischen Nutzen, den Perampanel bei Patienten mit fokaler Epilepsie hat. Sie sind von besonders großer Bedeutung für Patienten, die mehrere Antiepileptika ausprobiert haben oder mehrere Präparate gleichzeitig einnehmen und weiterhin häufig Anfälle haben" , so Professor Bernard Steinhoff

Erste Praxisdaten zu Fycompa® (Perampanel) zeigen "eindeutigen therapeutischen Nutzen" [Published PR Newswire - May 09 2013]

"Wir freuen uns sehr, dass Lenvatinib den "Orphan Drug"-Status in den 27 Ländern der EU sowie der Schweiz erhalten hat. Der "Orphan Drug" Status unterstreicht den ungedeckten Behandlungsbedarf von Menschen mit radiojod-refraktärem differenziertem Schilddrüsenkarzinom (RRDTC) und das wichtige Potenzial für dieses Prüfpräparat. Eisai engagiert sich dafür, Menschen, die an dieser schwer zu behandelnden Form von Schilddrüsenkrebs leiden, eine neue Option zu bieten" , kommentiert Gary Hendler Lenvatinib wurde von Eisai in Europa und Japan

EU-Zulassungsbehörden erteilen Lenvatinib von Eisai "Orphan Drug"-Status für die Behandlung von r ... [Published PR Newswire - May 07 2013]

More Content

sort by: Date \| Relevance
CORRECTED-Amag investigates anemia drug after r... [Published Reuters UK - 11 hours ago]
Amag says anemia drug caused fatal reaction in ... [Published Reuters - 14 hours ago]
Geneva cancer specialist wins new US award [Published GenevaLunch - May 17 2013]
First-in-class Fycompa® (perampanel) Pooled Piv... [Published Sys-Con Australia - May 13 2013]
Erste Praxisdaten zu Fycompa® (Perampanel) zeig... [Published PR Newswire - May 09 2013]
EISAI FILES FOR EARLIER USE OF HALAVEN® (ERIBUL... [Published PharmiWeb - May 08 2013]
Roche's Kadcyla Breast Cancer Drug Approved For... [Published FOXBusiness.com - May 07 2013]
Roche's Kadcyla Breast Cancer Drug Approved For... [Published Capital.gr - May 07 2013]
EU Regulatory Authorities Grant Orphan Status T... [Published Reuters UK - May 07 2013]
EU-Zulassungsbehörden erteilen Lenvatinib von E... [Published PR Newswire - May 07 2013]
Las autoridades reguladoras de la UE conceden e... [Published PR Newswire - May 07 2013]
EU Regulatory Authorities Grant Orphan Status t... [Published FinanzNachrichten.de - May 07 2013]
Arena pulls obesity drug Belviq application in EU [Published PMLive - May 03 2013]
Arena pulls file for weight loss drug Belviq in EU [Published Pharma Times - May 03 2013]
Arena Pharmaceuticals Provides Corporate Update... [Published KWQC - May 02 2013]
Arena Pharmaceuticals Provides Corporate Update... [Published NewsBlaze - May 02 2013]
Foundation ups drugs checks [Published Swiss Info - Apr 15 2013]
Stock Losers: Rambus Inc, Ruby Tuesday, Nexstar... [Published SBWire - Apr 12 2013]
Swissmedic and Swiss Red Cross Present National... [Published Business Wire Health News - Apr 03 2013]
Fycompa® (Perampanel) wird als erstes Epilepsie... [Published PR Newswire - Mar 19 2013]
Mise à disposition en Suisse de Fycompa® (peram... [Published PR Newswire - Mar 19 2013]
Fycompa® (perampanel), capostipite di una nuova... [Published PR Newswire - Mar 19 2013]
Se presenta en Suiza Fycompa® (perampanel), un ... [Published PR Newswire - Mar 19 2013]
Fycompa® (Perampanel) als erstes Medikament ein... [Published PR Newswire - Jan 08 2013]
Se aprueba Fycompa® (perampanel), en suiza un n... [Published PR Newswire - Jan 08 2013]
Fycompa® (perampanel), nouveau traitement innov... [Published PR Newswire - Jan 08 2013]
Fycompa® (perampanel), capostipite di una nuova... [Published PR Newswire: Health - Jan 08 2013]
Hovione et Solvias annoncent une collaboration ... [Published PR Newswire - Nov 28 2012]
Health Canada, Swissmedic lift precautionary ho... [Published PharmaBiz - Nov 01 2012]
Roche to present new data in HER2 positive brea... [Published PharmaBiz - Sep 25 2012]